We are studying how hematopoietic cell fate is specified, maintained, and eventually modified or reversed. Inspired from the fields of stem cell biology, immunology, and cancer we use an interdisciplinary approach to mechanistically understand hematopoietic and immune cell identities and translate our findings into novel gene and cell therapies.
Single-Cell Transcriptional Profiling Informs Efficient Reprogramming of Human Somatic Cells to Cross-Presenting Dendritic Cells
Fábio F. Rosa, Cristiana F. Pires, Ilia Kurochkin, Evelyn Halitzki, Tasnim Zahan, Nejc Arh, Olga Zimmermannová, Alexandra G. Ferreira, Hongzhe Li, Stefan Karlsson, Stefan Scheding, Carlos-Filipe Pereira
March 4, 2022 / Vol. 7, No. 69
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Olga Zimmermannova, Inês Caiado, Alexandra G. Ferreira and Carlos-Filipe Pereira
July 21, 2021 / Volume 12, Article 714822
Frontiers in Immunology
We are a diverse group – molecular biologists, MDs, PharmDs, tumor immunologists, stem cell biologists and computational scientists – at all career stages. We architect strategies to dissect and manipulate immune cell identity.
Looking for an opportunity? Join our international team!
Camila Vazquez Echegaray Awarded a MSCA Postdoctoral Fellowship
Pereira Lab researcher Camila Vazquez Echegaray was awarded a Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship.
Eurostars-funded REPRINT Project Kick-off Meeting
The Pereira Lab took part in a meeting held by Asgard Therapeutics AB, together with consortium members InSphero and Antineo, that sets the official kick-off to the earlier announced Eurostars project.
Encoding Human Dendritic Cell Fate
PU.1, IRF8, and BATF3 cooperation and role in inflammatory signaling during programming of human cDC1-like cells was uncovered at the Pereira Lab.